Latest News

Hollings researchers uncovered data showing that women who survive cervical cancer are at greater risk of anal cancer years down the road.

MUSC is betting big on its own innovative culture, announcing launch of first venture fund: 1824 Health Ventures Fund I, LP.

The radiation therapy team MUSC Hollings Cancer Center Orangeburg is debuting the latest version of the True Beam linear accelerator.

A clinical trial at Hollings is looking for answers to a problem that Dr. Avi Siva saw was affecting her triple negative breast cancer patients.

An expanded physical therapy space for cancer survivors at MUSC Hollings Cancer Center opens possibilities for patients and the program.

A new microcredential from Hollings Cancer Center highlights the work of future cancer researchers, who are learning both science and compassion.

MUSC Hollings Cancer Center researchers are working on a new drug that destroys cancer cells' energy factories.

New trial to test whether quit-smoking medication works to help people to quit vaping.

MUSC students receive world-class training and make worldwide connections at an international redox training program in Hungary.

MUSC student Thomas Blouin will use an NCI fellowship to study how a chemical that doesn't seem to change DNA still causes cancer.